News

Prolor has entered into an evaluation and option agreement with Yeda. Under the terms of the agreement, Prolor may obtain from Yeda a license to develop a number

Phase Forward has acquired privately-held Maaguzi, a provider of Web-based, electronic patient reported outcomes (ePRO) and late phase solutions, for $11 million. This acquisition extends Phase Forward’s integrated

Avila has entered into an option agreement with Novartis to develop novel covalent drug program from Avila’s research pipeline, in combination with an equity investment. The agreement includes

FDA has accepted CyDex’s Investigational New Drug (IND) application for a clinical study of Captisol-enabled melphalan HCL (CDX-353). Melphalan is an FDA-approved low dose chemotherapy for multiple myeloma

Insmed, a biopharmaceutical company, will cease the supply of IPLEX to any new patients. In addition, the company will not initiate further clinical trials with IPLEX at this

The revenue increase was primarily due to $34.2 million of incremental revenue provided by our Health Management segment principally as a result of incremental revenues from recently acquired

Novo Nordisk has provided the data of liraglutide study. It showed that once-daily liraglutide (an investigational treatment for type 2 diabetes) leads to significant and sustained reductions in

Compass Pharma Services has upgraded its production facility to include ISO Class 8 (ISO 14644) specifications in order to provide packaging services for certain high-potency pharmaceutical products. The

Schering-Plough’s investigational drug SAPHRIS (asenapine) met the primary endpoint over one year of treatment in an extension study in patients with predominant, persistent negative symptoms of schizophrenia. Negative